Testing delgocitinib cream for lichen sclerosus
Treatments studied
Part of Skin clinical trials.
This trial tests a cream called delgocitinib for adults with lichen sclerosus in the genital area. It aims to see if the cream can safely and effectively reduce symptoms over 52 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have lichen sclerosus in the genital or anal area, with a diagnosis confirmed by a doctor and usually a biopsy.
- Your disease must be mild, moderate, or severe (rated by your doctor).
- You cannot have used certain immune-suppressing medications (like methotrexate, cyclosporine, or oral steroids) in the past 4 weeks.
- You cannot have used medicated creams (like steroids) on the genital area in the past 2 weeks.
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the trial (if female).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if laser therapy works as well as clobetasol cream for vulvar lichen sclerosus after a previous course of the cream. It aims to offer an alternative treatment option for people who have already completed the standard cream therapy.
This study tests a new medication for people with moderate to severe lichen planus that has not improved with topical treatments. The goal is to see if it reduces symptoms and improves quality of life.
This study tests an oral medication called delgocitinib, which targets certain enzymes linked to inflammation, in people with central centrifugal cicatricial alopecia (CCCA) or lichen planopilaris (LPP). It aims to see if the drug is safe and if it changes biomarkers (biological signals) related to these conditions.
This study tests a new injectable medication called nemolizumab to see if it can reduce itching in women with lichen sclerosus affecting the genital area. If you have severe itching that hasn't been fully controlled by steroid creams, this might be an option to explore.
This study tests whether a new topical treatment, StrataMGT, can reduce symptoms of vulvar lichen sclerosus. It is for women with moderate to severe symptoms who are already using a stable topical prescription.
This study tests a cream that targets inflammation in the skin for people with early-stage mycosis fungoides, a type of lymphoma. It may help relieve symptoms and slow the disease without stronger treatments.
Hear when a new Lichen Sclerosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.